Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110019/S142

XIENCE Alpine; XIENCE Sierra; XIENCE PROs; XIENCE Skypoint Everolimus Eluting Coronary Stent Systems

Abbott Vascular · Decision date Jul 31, 2026

FDA DECISIONP110019/S142

What did the FDA approve?

FDA records P110019/S142 as a supplement to PMA P110019, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 31, 2026.

FDA approval order statement

an alternate supplier for the secondary packaging
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Jul 31, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P110019/S142
Regulatory pathway
PMA supplement
Product code
NIQ
Decision code
APPR
Decision date
Jul 31, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P110019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110019 · Original PMA

    Xience Skypoint Everolimus Eluting Coronary Stent System

  2. P110019/S136 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Sten

  3. P110019/S137 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine OTW)

  4. P110019/S138 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine), XIENCE Sierra Everolimus Eluting Coronary Stent

  5. P110019/S139 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Stent

  6. P110019/S140 · Related supplement

    XIENCE Alpine Everolimus Eluting Coronary Stent System; XIENCE Sierra Everolimus Eluting Coronary Stent System; XIENCE P

  7. P110019/S142 received

    Application receipt date recorded by FDA.

  8. P110019/S141 · Related supplement

    XIENCE Alpine, XIENCE Sierra, XIENCE PRO S, and XIENCE Skypoint Everolimus Eluting Coronary Stent Systems

  9. P110019/S142 · FDA decision

    Real-Time Process

  10. P110019/S144 · Related supplement

    XIENCE PROS Everolimus Eluting Coronary Stent System (XIENCE PRO5); XIENCE Skypoint Everolimus Eluting Coronary Stent Sy

  11. P110019/S145 · Related supplement

    XIENCE PRO5 Everolimus Eluting Coronary Stent System (XIENCE PRO5), XIENCE Skypoint Everolimus Eluting Coronary Stent Sy

Timeline entries are records held by MedtechLedger for P110019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110019

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott VascularPMA approvalNov 1, 2011FDA
Abbott VascularPMA supplementAug 16, 2025FDA
Abbott VascularPMA supplementOct 22, 2025FDA
Abbott VascularPMA supplementFeb 3, 2026FDA
Abbott VascularPMA supplementFeb 5, 2026FDA
Abbott VascularPMA supplementFeb 13, 2026FDA
Abbott VascularPMA supplementMay 22, 2026FDA
Abbott VascularPMA supplementAug 28, 2026FDA
Abbott VascularPMA supplementOct 1, 2026FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records